Lates News

According to Every AI, on April 30th, China Postal Securities released a research report giving a buy rating to Jinhe Biotechnology (002688.SZ). The main reasons for the rating include: 1) the prices and quantities of chemical drugs are rising, while vaccines are under pressure; 2) the release of new production capacity will further increase prices and quantities in the next 25 years. (Daily Economic News)